abstract |
Disclosed is a pharmaceutical composition comprising the APL peptide identified as SEQ ID NO. 1, as an inhibitor of a hyperinflammatory state characterised by an increase in cytokines or interleukins and inflammatory molecules, the concentration of which increases until reaching a state defined as "cytokine storm". The sucrose concentrations in the composition increase the biological activity of the peptide, facilitating its intravenous application. Said peptide in a pharmaceutical composition is useful for the production of a drug for treating hyperinflammation-related diseases, such as COVID-19, dengue, macrophage activation syndrome, respiratory sepsis and diseases associated with chimeric antigen receptor T-cell therapies, and acute respiratory distress syndrome. Also disclosed is a method for treating said diseases by administering a therapeutically effective amount of the composition. |